MARKET

OCGN

OCGN

Ocugen Inc
NASDAQ
1.030
-0.050
-4.63%
After Hours: 1.050 +0.02 +1.97% 19:57 03/18 EDT
OPEN
1.090
PREV CLOSE
1.080
HIGH
1.220
LOW
1.010
VOLUME
10.73M
TURNOVER
0
52 WEEK HIGH
1.280
52 WEEK LOW
0.3450
MARKET CAP
264.20M
P/E (TTM)
-3.1761
1D
5D
1M
3M
1Y
5Y
Ocugen Inc Bolsters Leadership with New CMO Appointment
TipRanks · 15h ago
Ocugen promotes Huma Qamar as Chief Medical Officer
Healthcare Ocugen promotes Huma Qamar as Chief Medical Officer. Qamar's expertise spans gene and cell therapy, vaccines, oncology, dermatology, and infectious diseases. Oc Eugen, Inc. (OCGN) is a biopharmaceutical company.
Seeking Alpha · 17h ago
Ocugen Names Qamar Chief Medical Officer
NASDAQ · 18h ago
Press Release: Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer
Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer. Dr. Qamar is a distinguished healthcare professional with a rich background in clinical research. Ocugen is a biotechnology company focused on discovering and developing novel gene and cell therapies and vaccines.
Dow Jones · 18h ago
Weekly Report: what happened at OCGN last week (0311-0315)?
Weekly Report · 18h ago
Weekly Report: what happened at OCGN last week (0304-0308)?
Weekly Report · 03/11 10:23
Ocugen to Present at Investing in Cures Summit
Ocugen is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines. Dr. Shankar Musunuri will be a panelist at the Investing in Cures Summit 2024 from March 8-9, 2024.
Barchart · 03/06 06:30
Weekly Report: what happened at OCGN last week (0226-0301)?
Weekly Report · 03/04 10:25
More
About OCGN
Ocugen, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines that improve health for patients across the globe. The Company's technology pipeline includes modifier gene therapy platform, regenerative medicine cell therapy platform, and biologic therapies for retinal diseases. It is developing COVAXIN, which is a whole-virion inactivated intramuscular COVID-19 vaccine candidate for the North American market. It is also developing a inhaled mucosal vaccine platform, which includes OCU500, a bivalent COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and bivalent COVID-19 vaccine. Its modifier gene therapy platform is focused on addressing various retinal diseases, including retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), and Stargardt disease, with a single mutation-agnostic therapy.

Webull offers Ocugen Inc stock information, including NASDAQ: OCGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OCGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OCGN stock methods without spending real money on the virtual paper trading platform.